{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:14:06Z","timestamp":1788556446677,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omta.2026.201707","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:48:03Z","timestamp":1771606083000},"page":"201707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical evaluation of INS1201 AAV9-micro-dystrophin via CSF administration as a potential therapy for Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"34","author":[{"given":"Gretchen","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Kaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferraiuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Slaiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Casanova-Vallve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Julazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haunani","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Renteria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiya","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaedyn","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McAlonis-Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. David","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"TreDenick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Bayless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kozial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Forespring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Molony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Bremner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Tsusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samit","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8301-1626","authenticated-orcid":false,"given":"Brian","family":"Kaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201707_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201707_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omta.2026.201707_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/dmcn.15788","article-title":"Reference curves of motor function outcomes in young steroid-naive males with Duchenne muscular dystrophy","volume":"66","author":"Hoskens","year":"2024","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.omta.2026.201707_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.nmd.2013.04.005","article-title":"Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network","volume":"23","author":"Connolly","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201707_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.pediatrneurol.2014.02.006","article-title":"One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development","volume":"50","author":"Connolly","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omta.2026.201707_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.nmd.2019.09.010","article-title":"Longitudinal natural history in young boys with Duchenne muscular dystrophy","volume":"29","author":"Coratti","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201707_bib7","doi-asserted-by":"crossref","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","article-title":"Life expectancy in duchenne muscular dystrophy: Reproduced individual patient data meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201707_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3233\/JND-220816","article-title":"Characterizing the occurrence of key clinical milestones in duchenne muscular dystrophy in the United States using real-world data","volume":"9","author":"Szabo","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2026.201707_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and Becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.omta.2026.201707_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omta.2026.201707_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201707_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","article-title":"Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy","volume":"15","author":"Potter","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201707_bib13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.gt.3301259","article-title":"Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy","volume":"7","author":"Ferrer","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201707_bib14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201707_bib15","unstructured":"LUXTURNA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna."},{"key":"10.1016\/j.omta.2026.201707_bib16","unstructured":"ZOLGENSMA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma."},{"key":"10.1016\/j.omta.2026.201707_bib17","unstructured":"Food and Drug Administration (2025). FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy."},{"key":"10.1016\/j.omta.2026.201707_bib18","unstructured":"HEMGENIX. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix."},{"key":"10.1016\/j.omta.2026.201707_bib19","unstructured":"ROCTAVIAN. https:\/\/www.fda.gov\/vaccines-blood-biologics\/roctavian."},{"key":"10.1016\/j.omta.2026.201707_bib20","unstructured":"ELEVIDYS. https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys."},{"key":"10.1016\/j.omta.2026.201707_bib21","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/ijms25021050","article-title":"Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201707_bib22","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201707_bib23","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.nmd.2019.06.307","article-title":"O.24Biodistribution of onasemnogene abeparvovec (AVXS-101) DNA, mRNA, and SMN protein in human tissue","volume":"29","author":"Kaspar","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201707_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201707_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201707_bib26","article-title":"Adeno-associated virus (AAV)-mediated gene therapy for Duchenne muscular dystrophy: The issue of transgene persistence","volume":"12","author":"Manini","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omta.2026.201707_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of Duchenne muscular dystrophy","volume":"32","author":"Potter","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201707_bib28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib29","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2026.201707_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201707_bib32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201707_bib33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/hum.2022.29211.bfs","article-title":"Food and Drug Administration lifts clinical hold on Pfizer Duchenne muscular dystrophy gene therapy linked to patient death","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201707_bib34","series-title":"Sarepta Therapeutics Shares Safety Update on ELEVIDYS","year":"2025"},{"key":"10.1016\/j.omta.2026.201707_bib35","unstructured":"Sarepta Therapeutics (2025). Sarepta provides safety update for ELEVIDYS and initiates steps to strengthen safety in non-ambulatory individuals with duchenne. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-provides-safety-update-elevidys-and-initiates-steps."},{"key":"10.1016\/j.omta.2026.201707_bib36","unstructured":"Food and Drug Administration (2025). FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requests-sarepta-therapeutics-suspend-distribution-elevidys-and-places-clinical-trials-hold."},{"key":"10.1016\/j.omta.2026.201707_bib37","unstructured":"Food and Drug Administration (2025). FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal."},{"key":"10.1016\/j.omta.2026.201707_bib38","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14712598.2024.2394477","article-title":"The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process","volume":"24","author":"Bhattacharyya","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib39","unstructured":"Novartis (2024). Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA. https:\/\/www.novartis.com\/news\/media-releases\/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-study-meets-primary-endpoint-children-and-young-adults-sma."},{"key":"10.1016\/j.omta.2026.201707_bib40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymthe.2020.09.033","article-title":"AAV9 gene therapy increases lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease","volume":"29","author":"Johnson","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101168","article-title":"Intrathecal delivery of a bicistronic AAV9 vector expressing beta-hexosaminidase A corrects Sandhoff disease in a murine model: A dosage study","volume":"32","author":"Ryckman","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201707_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ymthe.2020.11.012","article-title":"Pre-clinical gene therapy with AAV9\/AGA in aspartylglucosaminuria mice provides evidence for clinical translation","volume":"29","author":"Chen","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib44","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201707_bib45","unstructured":"Taysha Gene Therapies. Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1\/2 Trials Evaluating TSHA-102 in Rett Syndrome. https:\/\/ir.tayshagtx.com\/news-releases\/news-release-details\/taysha-gene-therapies-announces-positive-clinical-data-across."},{"key":"10.1016\/j.omta.2026.201707_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201707_bib47","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/j.ymthe.2023.07.013","article-title":"Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates","volume":"31","author":"Powers","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib48","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.ymthe.2019.06.015","article-title":"Gene therapy corrects brain and behavioral pathologies in CLN6-batten disease","volume":"27","author":"Cain","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib49","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib50","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: Promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201707_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201707_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74192-9","article-title":"Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss","volume":"10","author":"Massopust","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201707_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13395-015-0041-y","article-title":"Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia","volume":"5","author":"Duddy","year":"2015","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omta.2026.201707_bib54","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0960-8966(01)00232-2","article-title":"Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-dystrophin\/utrophin-and laminin alpha2-deficient mice","volume":"11","author":"Connolly","year":"2001","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201707_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0022-510X(94)00276-T","article-title":"mdx mice show progressive weakness and muscle deterioration with age","volume":"129","author":"Pastoret","year":"1995","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omta.2026.201707_bib56","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1152\/japplphysiol.00776.2015","article-title":"Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points","volume":"122","author":"Capogrosso","year":"2017","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.omta.2026.201707_bib57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jmor.1052210207","article-title":"Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb","volume":"221","author":"Burkholder","year":"1994","journal-title":"J. Morphol."},{"key":"10.1016\/j.omta.2026.201707_bib58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1098\/rspb.1992.0058","article-title":"Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic mdx mice","volume":"248","author":"Head","year":"1992","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.omta.2026.201707_bib59","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF00121296","article-title":"Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch","volume":"14","author":"Moens","year":"1993","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.omta.2026.201707_bib60","doi-asserted-by":"crossref","first-page":"C704","DOI":"10.1152\/ajpcell.00122.2021","article-title":"Dystrophin-negative slow-twitch soleus muscles are not susceptible to eccentric contraction induced injury over the lifespan of the mdx mouse","volume":"321","author":"Kiriaev","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.omta.2026.201707_bib61","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archneur.1961.00450110050006","article-title":"Serum creatine phosphokinase. Activity in progressive muscular dystrophy and neuromuscular diseases","volume":"4","author":"Okinaka","year":"1961","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.omta.2026.201707_bib62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-4684-5865-7_29","article-title":"Mdx mouse as therapeutic model system: development and implementation of phenotypic monitoring","volume":"280","author":"Hudecki","year":"1990","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omta.2026.201707_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10081241","article-title":"A blood biomarker for Duchenne muscular dystrophy shows that oxidation state of albumin correlates with protein oxidation and damage in mdx muscle","volume":"10","author":"Al-Mshhdani","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.omta.2026.201707_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2008.03.008","article-title":"Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy","volume":"31","author":"Grounds","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omta.2026.201707_bib65","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.ymthe.2023.07.020","article-title":"Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery","volume":"31","author":"Hudry","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201707_bib66","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201707_bib67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(87)90219-X","article-title":"Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles","volume":"80","author":"Carnwath","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omta.2026.201707_bib68","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0022-2828(03)00245-1","article-title":"Effect of muscle origin and phenotype on satellite cell muscle-specific gene expression","volume":"35","author":"LaFramboise","year":"2003","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.omta.2026.201707_bib69","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201707_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41536-018-0045-4","article-title":"Humanizing the mdx mouse model of DMD: the long and the short of it","volume":"3","author":"Yucel","year":"2018","journal-title":"NPJ Regen. Med."},{"key":"10.1016\/j.omta.2026.201707_bib71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2021.04.015","article-title":"Skeletal muscle fibers count on nuclear numbers for growth","volume":"119","author":"Prasad","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.omta.2026.201707_bib72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201707_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201707_bib74","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s00018-020-03706-5","article-title":"Cerebrospinal fluid outflow: a review of the historical and contemporary evidence for arachnoid villi, perineural routes, and dural lymphatics","volume":"78","author":"Proulx","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omta.2026.201707_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201707_bib76","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1523\/JNEUROSCI.2158-19.2020","article-title":"Synaptic specificity and application of anterograde transsynaptic AAV for probing neural circuitry","volume":"40","author":"Zingg","year":"2020","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omta.2026.201707_bib77","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/hum.2013.189","article-title":"Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport","volume":"25","author":"Castle","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201707_bib78","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.1086137","article-title":"Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model","volume":"301","author":"Kaspar","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201707_bib79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fnana.2019.00093","article-title":"Adeno-associated virus technologies and methods for targeted neuronal manipulation","volume":"13","author":"Haery","year":"2019","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.omta.2026.201707_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101519","article-title":"Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain","volume":"33","author":"Foltz","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201707_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1815","article-title":"Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy","volume":"15","author":"Birch","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201707_bib82","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1469-8749.2007.00907.x","article-title":"Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation","volume":"49","author":"Minamoto","year":"2007","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.omta.2026.201707_bib83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.20646","article-title":"Weekly oral prednisolone improves survival and strength in male mdx mice","volume":"35","author":"Keeling","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omta.2026.201707_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069194","article-title":"Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice","volume":"8","author":"Echigoya","year":"2013","journal-title":"PLoS One"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:31:37Z","timestamp":1788553897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X2600042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3117387X2600042X"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201707","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of INS1201 AAV9-micro-dystrophin via CSF administration as a potential therapy for Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201707"}}